Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Bleomycin

J M Bennett, S D Reich

Annals of Internal Medicine

|June 1, 1979

Summary

This summary is machine-generated.

Bleomycin is FDA-approved for specific cancers like squamous cell carcinomas and lymphomas. Its use is limited to these indications due to potential lung and mucous membrane toxicity, warranting cautious application.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T.

Leukemia research·2021

Same author

A Case of Acute Eosinophilic Leukemia with a Novel <i>PHF</i>6 Mutation.

Case reports in hematology·2021

Same author

A case of Burkitt Leukemia: Revisiting the prognostic value of lactate dehydrogenase.

Leukemia research·2020

Same author

Publisher Correction: GloPL, a global data base on pollen limitation of plant reproduction.

Scientific data·2019

Same author

GloPL, a global data base on pollen limitation of plant reproduction.

Scientific data·2018

Same author

Smokers Display Reduced Glucocorticoid Sensitivity Prior to Symptomatic Chronic Disease Development.

Annals of behavioral medicine : a publication of the Society of Behavioral Medicine·2018

Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026

Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026

Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026

Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026

Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026

Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026

See all related articles

Area of Science:

Oncology
Pharmacology

Background:

Bleomycin received FDA approval in 1975.
It is indicated for squamous cell carcinomas, testicular cancers, and malignant lymphomas.

Purpose of the Study:

To review the therapeutic applications and limitations of bleomycin.
To highlight safety considerations for bleomycin use.

Main Methods:

Literature review of bleomycin's efficacy and toxicity.
Analysis of clinical evidence for bleomycin in various malignancies.

Main Results:

Bleomycin demonstrates significant activity against specific cancers.
Limited evidence supports bleomycin's efficacy in other malignancies.
Toxicity, particularly pulmonary and mucosal, is a key concern.

Conclusions:

Bleomycin remains a valuable agent for its approved indications.
Physician caution is advised due to toxicity, especially in non-research settings.
The role of bleomycin in combination chemotherapy requires further investigation.